Literature DB >> 34491364

Quality of Life Improvements in Patients With Chronic Myeloid Leukemia After Stopping Long-Term Therapy: Who Can Benefit the Most?

Fabio Efficace1, Michele Baccarani2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34491364      PMCID： PMC8755488          DOI： 10.1093/jnci/djab185

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  14 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.

Authors:  Fabio Efficace; Michele Baccarani; Massimo Breccia; Giuliana Alimena; Gianantonio Rosti; Francesco Cottone; Giorgio Lambertenghi Deliliers; Claudia Baratè; Antonella Russo Rossi; Giuseppe Fioritoni; Luigia Luciano; Diamante Turri; Bruno Martino; Francesco Di Raimondo; Melissa Dabusti; Micaela Bergamaschi; Pietro Leoni; Maria Pina Simula; Luciano Levato; Stefano Ulisciani; Dino Veneri; Simona Sica; Alessandro Rambaldi; Marco Vignetti; Franco Mandelli
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

3.  Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Authors:  Johan Richter; Stina Söderlund; Anna Lübking; Arta Dreimane; Kourosh Lotfi; Berit Markevärn; Anders Själander; Susanne Saussele; Ulla Olsson-Strömberg; Leif Stenke
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

4.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Authors:  Hannah Bower; Magnus Björkholm; Paul W Dickman; Martin Höglund; Paul C Lambert; Therese M-L Andersson
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

5.  Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.

Authors:  Joon Seong Park; Sung-Eun Lee; Seong Hyun Jeong; Eun-Jung Jang; Mi-Yeon Choi; Hyeoung-Joon Kim; Yeo-Kyeoung Kim; Sung-Hyun Kim; Dae Young Zang; Sukjoong Oh; Dong Hoe Koo; Hawk Kim; Young Rok Do; Jae-Yong Kwak; Jeong-A Kim; Dae-Young Kim; Yeung-Chul Mun; Won Sik Lee; Myung Hee Chang; Jinny Park; Ji Hyun Kwon; Dong-Wook Kim
Journal:  Leuk Lymphoma       Date:  2015-06-12

6.  Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.

Authors:  Elizabeth A Hahn; G Alastair Glendenning; Mark V Sorensen; Stacie A Hudgens; Brian J Druker; Francois Guilhot; Richard A Larson; Stephen G O'Brien; Deborah G Dobrez; Martee L Hensley; David Cella
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

7.  Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.

Authors:  Fabio Efficace; Alessandra Iurlo; Andrea Patriarca; Fabio Stagno; Ping-Chong Bee; Geneviève Ector; Isabella Capodanno; Chiara Elena; Massimiliano Bonifacio; Nicole M A Blijlevens; Giovanni Caocci; Chonghua Wan; Elisabetta Abruzzese; Massimo Breccia; Francesco Cottone; Iris Okumura; Simone Oerlemans; Nicola Cascavilla; Francesco Albano; Vamsi Kota; Monika Sztankay; Maria Cristina Miggiano; Susanne Saussele; Nicola Di Renzo; Federica Sorà; Fausto Castagnetti; Michele Baccarani; Marco Vignetti; Gianantonio Rosti
Journal:  Leuk Lymphoma       Date:  2020-11-06

8.  Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.

Authors:  Ehab Atallah; Charles A Schiffer; Jerald P Radich; Kevin P Weinfurt; Mei-Jie Zhang; Javier Pinilla-Ibarz; Vamsi Kota; Richard A Larson; Joseph O Moore; Michael J Mauro; Michael W N Deininger; James E Thompson; Vivian G Oehler; Martha Wadleigh; Neil P Shah; Ellen K Ritchie; Richard T Silver; Jorge Cortes; Li Lin; Alexis Visotcky; Arielle Baim; Jill Harrell; Bret Helton; Mary Horowitz; Kathryn E Flynn
Journal:  JAMA Oncol       Date:  2021-01-01       Impact factor: 31.777

9.  Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Authors:  A Hochhaus; T Masszi; F J Giles; J P Radich; D M Ross; M T Gómez Casares; A Hellmann; J Stentoft; E Conneally; V García-Gutiérrez; N Gattermann; W Wiktor-Jedrzejczak; P D le Coutre; B Martino; S Saussele; H D Menssen; W Deng; N Krunic; V Bedoucha; G Saglio
Journal:  Leukemia       Date:  2017-02-20       Impact factor: 11.528

10.  Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.

Authors:  Kristin M Phillips; Javier Pinilla-Ibarz; Eduardo Sotomayor; Morgan R Lee; Heather S L Jim; Brent J Small; Lubomir Sokol; Jeffrey Lancet; Sara Tinsley; Kendra Sweet; Rami Komrokji; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2012-11-20       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.